- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA makes 9 observations over Wockhardt's plant in Shendra
New Delhi: The USFDA has made nine 'observations' highlighting violations of its norms at homegrown drug maker Wockhardt's new facility at Shendra in Aurangabad.
The company, whose shares slumped 15.04 per cent on NSE to close at Rs 1,287.00 today, however, said being a new unit, there is no export from the Shendra facility to the US.
"Inspection of our manufacturing unit at Shendra, Aurangabad by USFDA has since been completed. USFDA has made nine observations for which appropriate reply would be submitted to the inspecting authority in due course," Wockhardt Ltd said in a regulatory filing.
Without disclosing details of the observations, it further said: "The Shendra manufacturing unit is a new facility and presently there are no supply of products from the said unit to the US markets."
The observations were made by the USFDA in the form of Form 483, which is issued to a company management at the conclusion of an inspection, highlighting any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related laws.
It emerged yesterday that 62,555 bottles of anti-biotic Azithromycin tablets manufactured by Wockhardt are being recalled by PD-Rx Pharmaceuticals Inc in the US market.
The tablets are in the strengths of 250 mg (45,022 bottles) and 500 mg (17,533 bottles)
The company, whose shares slumped 15.04 per cent on NSE to close at Rs 1,287.00 today, however, said being a new unit, there is no export from the Shendra facility to the US.
"Inspection of our manufacturing unit at Shendra, Aurangabad by USFDA has since been completed. USFDA has made nine observations for which appropriate reply would be submitted to the inspecting authority in due course," Wockhardt Ltd said in a regulatory filing.
Without disclosing details of the observations, it further said: "The Shendra manufacturing unit is a new facility and presently there are no supply of products from the said unit to the US markets."
The observations were made by the USFDA in the form of Form 483, which is issued to a company management at the conclusion of an inspection, highlighting any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related laws.
It emerged yesterday that 62,555 bottles of anti-biotic Azithromycin tablets manufactured by Wockhardt are being recalled by PD-Rx Pharmaceuticals Inc in the US market.
The tablets are in the strengths of 250 mg (45,022 bottles) and 500 mg (17,533 bottles)
Next Story